NCT01315132 2026-03-19
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
Clinical Trials
4,634 trialsNCT02693535 2026-03-19
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT03412396 2026-03-19
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03573648 2026-03-19
ImmunoADAPT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03654131 2026-03-19
LAVA-CRLM
Rigshospitalet, Denmark
Phase 2 Active not recruiting
NCT03950609 2026-03-19
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04415944 2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
NCT05029141 2026-03-19
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2 Active not recruiting
NCT05659563 2026-03-19
EMPRESS
MedSIR
Phase 2 Completed
NCT05797870 2026-03-19
Lip-Re2
Center Eugene Marquis
Phase 2 Suspended
NCT05923190 2026-03-19
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT06379360 2026-03-19
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07132190 2026-03-19
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Brigham and Women's Hospital
Phase 2 Recruiting
NCT07149207 2026-03-19
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
Medical University of South Carolina
Phase 2 Not yet recruiting
NCT07172256 2026-03-19
CUE-101with Pembrolizumab for LA-HPV+HNSCCs
Yale University
Phase 2 Not yet recruiting
NCT07483359 2026-03-19
CONV3RSION
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
NCT02422641 2026-03-18
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT03301454 2026-03-18
E-DIS2
Centre Oscar Lambret
Phase 2 Terminated
NCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT03793361 2026-03-18
EREMISS
Centre Oscar Lambret
Phase 2 Completed
NCT04016142 2026-03-18
ACCRAPAN
Centre Oscar Lambret
Phase 2 Terminated
NCT04251949 2026-03-18
MuciLight
Centre Oscar Lambret
Phase 2 Completed
NCT04375384 2026-03-18
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT05020574 2026-03-18
Microbiome and Association With Implant Infections
University of California, San Francisco
Phase 2 Recruiting
NCT05272826 2026-03-18
BOREALIS
Canadian Myeloma Research Group
Phase 2 Recruiting
NCT05500391 2026-03-18
SUR-CAN
Centre Oscar Lambret
Phase 2 Recruiting
NCT05806931 2026-03-18
SCOTI
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT06258525 2026-03-18
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Cedars-Sinai Medical Center
Phase 2 Not yet recruiting
NCT06561360 2026-03-18
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06658405 2026-03-18
HPV2
Centre Oscar Lambret
Phase 2 Recruiting
NCT07010497 2026-03-18
IAPETUS
Asan Medical Center
Phase 2 Recruiting
NCT07209449 2026-03-18
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07283705 2026-03-18
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT07472933 2026-03-18
Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies
West China Hospital
Phase 2 Not yet recruiting
NCT07479628 2026-03-18
Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT07480733 2026-03-18
A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Not yet recruiting
NCT07480850 2026-03-18
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT07480863 2026-03-18
Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02114229 2026-03-17
SJATRT
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02135133 2026-03-17
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02482376 2026-03-17
Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer
Duke University
Phase 2 Active not recruiting
NCT02528955 2026-03-17
DIREKHT
University of Erlangen-Nürnberg Medical School
Phase 2 Completed
NCT02818920 2026-03-17
TOP 1501
Duke University
Phase 2 Completed
NCT03462342 2026-03-17
CAPRI
University of Pennsylvania
Phase 2 Completed
NCT03590171 2026-03-17
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany
Phase 2 Recruiting
NCT03799445 2026-03-17
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05023655 2026-03-17
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Prisma Health-Upstate
Phase 2 Terminated
NCT05436561 2026-03-17
Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting